Taohong Siwu Decoction exerts anticancer effects on breast cancer via regulating MYC, BIRC5, EGF and PIK3R1 revealed by HTS2 technology

Yu Gui,Yifei Dai,Yumei Wang,Shengrong Li,Lei Xiang,Yuqin Tang,Xue Tan,Tianli Pei,Xilinqiqige Bao,Dong Wang

DOI: https://doi.org/10.1016/j.csbj.2022.06.044

IF: 6.155

2022-01-01

Computational and Structural Biotechnology Journal

Abstract:Taohong Siwu Decoction (TSD), a classical gynecological prescription that was firstly reported 600 years ago, has been widely used in the adjuvant treatment of breast cancer (BRCA) in China. However, the mechanism of action of TSD in treating BRCA has remained unclear. Here, high-throughput sequencing-based high-throughput screening (HTS²) technology was used to reveal the molecular mechanism of TSD, combination with bioinformatics and systems pharmacology in this study. Firstly, our results showed that TSD exerts an anticancer effect on BRCA cells by inhibiting cell proliferation, migration and inducing apoptosis as well as cell-cycle arrest. And our results from HTS² suggested that herbs of TSD could significantly inhibit KRAS pathway and pathway in cancer, and activate apoptosis pathway, p53 pathway and hypoxia pathway, which may lead to the anticancer function of TSD. Further, we found that TSD clearly regulates <i>MYC, BIRC5, EGF,</i> and <i>PIK3R1</i> genes, which play an important role in the development and progression of tumor and have significant correlation with overall survival in BRCA patients. By molecular docking, we discovered that Pentagalloylglucose, a compound derived from TSD, might directly bind to and inhibit the function of BRD4, which is a reported transcriptional activator of <i>MYC</i> gene, and thus repress the expression of <i>MYC</i>. Taken together, this study explores the mechanism of TSD in anti-BRCA by combining HTS² technology, bioinformatics analysis and systems pharmacology.

biochemistry & molecular biology